Saturday, 31 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

AZERION WARRANTS: Massive 93% Decline In Last 10 Sessions

Loading stream...
(VIANEWS) - AZERION WARRANTS (AEX: AZRNW.AS) experienced a drastic 93.33% decline in the last 10 sessions, falling from €0.15 to €0.01 at 19:59 EST on Saturday. This marked the fifth consecutive session of losses for AZERION WARRANTS. The AEX-Index is also down 0.08% to €733.37, after two consecutive sessions of losses. AZERION WARRANTS's last closing price was €0.01, 0% below its 52-week high of €0.01.

Yearly Analysis

Based on the given information, AZERION WARRANTS's stock is currently trading at €0.01, which is significantly higher than its 52-week high of €0.01. This indicates that the stock has been performing well and has reached new highs in the past year. However, it's important to note that past performance is not indicative of future results, and investors should conduct their own research and analysis before making any investment decisions. More news about AZERION WARRANTS (AZRNW.AS).

Categories

stockMarket

Tags

Stock PriceAZRNW.ASAZERION WARRANTSPrice DownMarket Session NowStock Price DownStock Market NowMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com